About Transmembrane protease serine 11B
Transmembrane protease serine 11B (TMPRSS11B) is a protein
from Homo sapiens identified by UniProt accession
Q86T26, 416 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Transmembrane protease serine 11B |
| UniProt accession | Q86T26 |
| Gene | TMPRSS11B |
| Organism | Homo sapiens |
| Length | 416 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (34)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.21
- mean corpuscular hemoglobin concentration · score 0.21
- mean corpuscular hemoglobin · score 0.07
- esophageal squamous cell carcinoma · score 0.05
- oral squamous cell carcinoma · score 0.05
- esophageal adenocarcinoma · score 0.04
- Barrett's esophagus · score 0.04
- breast carcinoma · score 0.03
- low density lipoprotein cholesterol measurement · score 0.03
- serum metabolite measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86T26-F1 | alphafold | PREDICTED | 91.54 | — |
Amino-acid sequence (416 residues)
MYRHGISSQR SWPLWTTIFI FLGVAAILGV TIGLLVHFLA VEKTYYYQGD FHISGVTYND NCENAASQAS TNLSKDIETK MLNAFQNSSI YKEYVKSEVI KLLPNANGSN VQLQLKFKFP PAEGVSMRTK IKAKLHQMLK NNMASWNAVP ASIKLMEISK AASEMLTNNC CGRQVANSII TGNKIVNGKS SLEGAWPWQA SMQWKGRHYC GASLISSRWL LSAAHCFAKK NNSKDWTVNF GIVVNKPYMT RKVQNIIFHE NYSSPGLHDD IALVQLAEEV SFTEYIRKIC LPEAKMKLSE NDNVVVTGWG TLYMNGSFPV ILQEDFLKII DNKICNASYA YSGFVTDTML CAGFMSGEAD ACQNDSGGPL AYPDSRNIWH LVGIVSWGDG CGKKNKPGVY TRVTSYRNWI TSKTGL
Explore Transmembrane protease serine 11B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets